醫脈通(02192.HK)與富途信託訂立信託契據
格隆匯1月17日丨醫脈通(02192.HK)公吿,2022年1月17日,公司就根據股份獎勵計劃規則委任股份獎勵計劃獨立受託人與富途信託訂立信託契據。富途信託為根據香港法例第29章《受託人條例》第78(1)條註冊的信託公司,為獨立第三方,與公司及其任何關連人士並無關連。
董事會已決議於2022年1月17日根據股份獎勵計劃向承授人授出合共50萬份股份獎勵。承授人接受股份獎勵授出時的應付金額為每份股份獎勵0.00001美元。
向承授人授出的股份獎勵將根據本公司一般授權建議配發及發行50萬股新股份獲滿足。新股份將按每股面值0.00001美元配發及發行予富途信託(作為承授人的利益受託人)。將向聯交所申請批准該等新股份上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.